stoxline Quote Chart Rank Option Currency Glossary
  
Pliant Therapeutics, Inc. (PLRX)
12.85  0.12 (0.94%)    05-28 15:31
Open: 12.98
High: 13
Volume: 371,359
  
Pre. Close: 12.73
Low: 12.36
Market Cap: 775(M)
Technical analysis
2024-05-28 2:53:46 PM
Short term     
Mid term     
Targets 6-month :  16.92 1-year :  19.29
Resists First :  14.49 Second :  16.52
Pivot price 14.1
Supports First :  11.21 Second :  9.32
MAs MA(5) :  13.51 MA(20) :  13.85
MA(100) :  15.29 MA(250) :  16.37
MACD MACD :  -0.1 Signal :  0.1
%K %D K(14,3) :  7.5 D(3) :  20.8
RSI RSI(14): 39
52-week High :  24.73 Low :  11.21
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PLRX ] has closed above bottom band by 10.3%. Bollinger Bands are 25.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 13.94 - 14.07 14.07 - 14.15
Low: 12.4 - 12.56 12.56 - 12.66
Close: 12.54 - 12.81 12.81 - 12.97
Company Description

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Headline News

Tue, 28 May 2024
Pliant Therapeutics, Inc. (PLRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Movies UK

Mon, 27 May 2024
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Purchased by Franklin Resources Inc. - MarketBeat

Mon, 27 May 2024
Franklin Resources Inc. Acquires 62173 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Mon, 27 May 2024
Swiss National Bank Sells 2700 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Sun, 26 May 2024
Pliant Therapeutics (NASDAQ:PLRX) Shares Down 4.5% - Defense World

Fri, 24 May 2024
Pliant Therapeutics (NASDAQ:PLRX) Trading Down 4.5% - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 60 (M)
Held by Insiders 4.931e+007 (%)
Held by Institutions 6.3 (%)
Shares Short 7,460 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.9254e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -78 %
Return on Assets (ttm) 404 %
Return on Equity (ttm) -21.8 %
Qtrly Rev. Growth 248000 %
Gross Profit (p.s.) 0
Sales Per Share -28.48
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -116 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.45
Price to Cash Flow 2.1
Stock Dividends
Dividend 0
Forward Dividend 7.55e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android